Predictive value of circulating immune cell changes in response to PD-1 blockade and TKI therapy in patients with hepatocellular carcinoma
•Circulating immune cells have shown to have a correlation with the response to immunotherapy in hepatocellular carcinoma patients.•Circulating immune cells have the potential to serve as indicators of the response to immunotherapy, providing a means to monitor dynamic changes and optimize treatment...
Gespeichert in:
| Veröffentlicht in: | Clinics and research in hepatology and gastroenterology 2024-08, Vol.48 (7), p.102390, Article 102390 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 7 |
| container_start_page | 102390 |
| container_title | Clinics and research in hepatology and gastroenterology |
| container_volume | 48 |
| creator | Wang, Jianpeng Xiao, Ping Li, Xishan Wu, Wenyu Shi, Degang Lin, Wei Wu, Zuchang |
| description | •Circulating immune cells have shown to have a correlation with the response to immunotherapy in hepatocellular carcinoma patients.•Circulating immune cells have the potential to serve as indicators of the response to immunotherapy, providing a means to monitor dynamic changes and optimize treatment for HCC.•The number of circulating NK cells increased when patients with hepatocellular carcinoma received lenvatinib in combination with ICIs.•A low level of circulating CD3+t and CD4+t cells was associated with a poor prognosis.
Purpose: This study investigated the dynamic changes in circulating immune cells following immune checkpoint inhibitors (ICIs), tyrosine kinase inhibitors (TKIs), and interventional therapy in hepatocellular carcinoma (HCC).
Methods: HCC patients undergoing transarterial chemoembolization (TACE), TKI, and ICI treatment were included in the treatment group. Peripheral blood samples were collected from these patients before each cycle of PD-1 blockade treatment. Flow cytometry analysis was conducted to assess the composition of peripheral immune cells and identify PD-1-expressing T cells.
Results: The treatment group showed a median time-to-tumor progression (TTP) of 8 months and an overall survival (OS) of 19 months. In comparison, the control group had 6 months and 15 months respectively. These differences were statistically significant (P = 0.029 for TTP and P = 0.020 for OS). In HCC patients receiving Lenvatinib, more circulating natural killer (NK) cells were noted. After 1–2 cycles of PD-1 antibody treatment, a general decline in the proportion of circulating PD-1+T cells was found, indicating individual variations in response.
Conclusion: Circulating immune cells have the potential to serve as indicators of the response to immunotherapy, providing a means to monitor dynamic changes and optimize treatment for HCC. |
| doi_str_mv | 10.1016/j.clinre.2024.102390 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3063471791</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2210740124001116</els_id><sourcerecordid>3063471791</sourcerecordid><originalsourceid>FETCH-LOGICAL-c241t-94f82703c0f8bba6b9737974784cd011cde41ae3579cc7f90e7482ea97072fc73</originalsourceid><addsrcrecordid>eNp9kc1u1TAQhS1ERau2b4CQl2xy8V-vkw0SKgUqKrWLVmJnOZNJry-JHWznor4CT42jlC7xxh7rzDn2fIS85WzDGd9-2G9gcD7iRjChypWQDXtFToTgrNKK_3j9cmb8mJyntGdlqQtWa_6GHMu6FnIr-Qn5cxexc5DdAenBDjPS0FNwEebBZucfqRvH2SMFHAYKO-sfMVHnacQ0BZ-Q5kDvPlectkOAn7ZDan1H779f07zDaKenRTwVK_Q50d8u7-gOSx0Ww5IRKdgIzofRnpGj3g4Jz5_3U_Lw5er-8lt1c_v1-vLTTQVC8Vw1qq-FZhJYX7et3baNlrrRStcKOsY5dKi4RXmhGwDdNwy1qgXaRjMtetDylLxffacYfs2YshldWp5jPYY5Gcm2UmmuG16kapVCDClF7M0U3Wjjk-HMLCDM3qwgzALCrCBK27vnhLkdsXtp-jf2Ivi4CrD88-AwmgRlQlBQRIRsuuD-n_AXn7ScVg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3063471791</pqid></control><display><type>article</type><title>Predictive value of circulating immune cell changes in response to PD-1 blockade and TKI therapy in patients with hepatocellular carcinoma</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Wang, Jianpeng ; Xiao, Ping ; Li, Xishan ; Wu, Wenyu ; Shi, Degang ; Lin, Wei ; Wu, Zuchang</creator><creatorcontrib>Wang, Jianpeng ; Xiao, Ping ; Li, Xishan ; Wu, Wenyu ; Shi, Degang ; Lin, Wei ; Wu, Zuchang</creatorcontrib><description>•Circulating immune cells have shown to have a correlation with the response to immunotherapy in hepatocellular carcinoma patients.•Circulating immune cells have the potential to serve as indicators of the response to immunotherapy, providing a means to monitor dynamic changes and optimize treatment for HCC.•The number of circulating NK cells increased when patients with hepatocellular carcinoma received lenvatinib in combination with ICIs.•A low level of circulating CD3+t and CD4+t cells was associated with a poor prognosis.
Purpose: This study investigated the dynamic changes in circulating immune cells following immune checkpoint inhibitors (ICIs), tyrosine kinase inhibitors (TKIs), and interventional therapy in hepatocellular carcinoma (HCC).
Methods: HCC patients undergoing transarterial chemoembolization (TACE), TKI, and ICI treatment were included in the treatment group. Peripheral blood samples were collected from these patients before each cycle of PD-1 blockade treatment. Flow cytometry analysis was conducted to assess the composition of peripheral immune cells and identify PD-1-expressing T cells.
Results: The treatment group showed a median time-to-tumor progression (TTP) of 8 months and an overall survival (OS) of 19 months. In comparison, the control group had 6 months and 15 months respectively. These differences were statistically significant (P = 0.029 for TTP and P = 0.020 for OS). In HCC patients receiving Lenvatinib, more circulating natural killer (NK) cells were noted. After 1–2 cycles of PD-1 antibody treatment, a general decline in the proportion of circulating PD-1+T cells was found, indicating individual variations in response.
Conclusion: Circulating immune cells have the potential to serve as indicators of the response to immunotherapy, providing a means to monitor dynamic changes and optimize treatment for HCC.</description><identifier>ISSN: 2210-7401</identifier><identifier>ISSN: 2210-741X</identifier><identifier>EISSN: 2210-741X</identifier><identifier>DOI: 10.1016/j.clinre.2024.102390</identifier><identifier>PMID: 38823631</identifier><language>eng</language><publisher>France: Elsevier Masson SAS</publisher><subject>Aged ; Carcinoma, Hepatocellular - blood ; Carcinoma, Hepatocellular - drug therapy ; Carcinoma, Hepatocellular - immunology ; Chemoembolization, Therapeutic ; Circulating immune cells ; Female ; Hepatocellular carcinoma ; Humans ; Immune Checkpoint Inhibitors - therapeutic use ; Immunotherapy ; Killer Cells, Natural - immunology ; Liver Neoplasms - blood ; Liver Neoplasms - drug therapy ; Liver Neoplasms - immunology ; Male ; Middle Aged ; Phenylurea Compounds - therapeutic use ; Predictive Value of Tests ; Programmed Cell Death 1 Receptor - antagonists & inhibitors ; Protein Kinase Inhibitors - therapeutic use ; Quinolines - therapeutic use ; T-Lymphocytes - immunology</subject><ispartof>Clinics and research in hepatology and gastroenterology, 2024-08, Vol.48 (7), p.102390, Article 102390</ispartof><rights>2024 Elsevier Masson SAS</rights><rights>Copyright © 2024 Elsevier Masson SAS. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c241t-94f82703c0f8bba6b9737974784cd011cde41ae3579cc7f90e7482ea97072fc73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.clinre.2024.102390$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38823631$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Jianpeng</creatorcontrib><creatorcontrib>Xiao, Ping</creatorcontrib><creatorcontrib>Li, Xishan</creatorcontrib><creatorcontrib>Wu, Wenyu</creatorcontrib><creatorcontrib>Shi, Degang</creatorcontrib><creatorcontrib>Lin, Wei</creatorcontrib><creatorcontrib>Wu, Zuchang</creatorcontrib><title>Predictive value of circulating immune cell changes in response to PD-1 blockade and TKI therapy in patients with hepatocellular carcinoma</title><title>Clinics and research in hepatology and gastroenterology</title><addtitle>Clin Res Hepatol Gastroenterol</addtitle><description>•Circulating immune cells have shown to have a correlation with the response to immunotherapy in hepatocellular carcinoma patients.•Circulating immune cells have the potential to serve as indicators of the response to immunotherapy, providing a means to monitor dynamic changes and optimize treatment for HCC.•The number of circulating NK cells increased when patients with hepatocellular carcinoma received lenvatinib in combination with ICIs.•A low level of circulating CD3+t and CD4+t cells was associated with a poor prognosis.
Purpose: This study investigated the dynamic changes in circulating immune cells following immune checkpoint inhibitors (ICIs), tyrosine kinase inhibitors (TKIs), and interventional therapy in hepatocellular carcinoma (HCC).
Methods: HCC patients undergoing transarterial chemoembolization (TACE), TKI, and ICI treatment were included in the treatment group. Peripheral blood samples were collected from these patients before each cycle of PD-1 blockade treatment. Flow cytometry analysis was conducted to assess the composition of peripheral immune cells and identify PD-1-expressing T cells.
Results: The treatment group showed a median time-to-tumor progression (TTP) of 8 months and an overall survival (OS) of 19 months. In comparison, the control group had 6 months and 15 months respectively. These differences were statistically significant (P = 0.029 for TTP and P = 0.020 for OS). In HCC patients receiving Lenvatinib, more circulating natural killer (NK) cells were noted. After 1–2 cycles of PD-1 antibody treatment, a general decline in the proportion of circulating PD-1+T cells was found, indicating individual variations in response.
Conclusion: Circulating immune cells have the potential to serve as indicators of the response to immunotherapy, providing a means to monitor dynamic changes and optimize treatment for HCC.</description><subject>Aged</subject><subject>Carcinoma, Hepatocellular - blood</subject><subject>Carcinoma, Hepatocellular - drug therapy</subject><subject>Carcinoma, Hepatocellular - immunology</subject><subject>Chemoembolization, Therapeutic</subject><subject>Circulating immune cells</subject><subject>Female</subject><subject>Hepatocellular carcinoma</subject><subject>Humans</subject><subject>Immune Checkpoint Inhibitors - therapeutic use</subject><subject>Immunotherapy</subject><subject>Killer Cells, Natural - immunology</subject><subject>Liver Neoplasms - blood</subject><subject>Liver Neoplasms - drug therapy</subject><subject>Liver Neoplasms - immunology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Phenylurea Compounds - therapeutic use</subject><subject>Predictive Value of Tests</subject><subject>Programmed Cell Death 1 Receptor - antagonists & inhibitors</subject><subject>Protein Kinase Inhibitors - therapeutic use</subject><subject>Quinolines - therapeutic use</subject><subject>T-Lymphocytes - immunology</subject><issn>2210-7401</issn><issn>2210-741X</issn><issn>2210-741X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc1u1TAQhS1ERau2b4CQl2xy8V-vkw0SKgUqKrWLVmJnOZNJry-JHWznor4CT42jlC7xxh7rzDn2fIS85WzDGd9-2G9gcD7iRjChypWQDXtFToTgrNKK_3j9cmb8mJyntGdlqQtWa_6GHMu6FnIr-Qn5cxexc5DdAenBDjPS0FNwEebBZucfqRvH2SMFHAYKO-sfMVHnacQ0BZ-Q5kDvPlectkOAn7ZDan1H779f07zDaKenRTwVK_Q50d8u7-gOSx0Ww5IRKdgIzofRnpGj3g4Jz5_3U_Lw5er-8lt1c_v1-vLTTQVC8Vw1qq-FZhJYX7et3baNlrrRStcKOsY5dKi4RXmhGwDdNwy1qgXaRjMtetDylLxffacYfs2YshldWp5jPYY5Gcm2UmmuG16kapVCDClF7M0U3Wjjk-HMLCDM3qwgzALCrCBK27vnhLkdsXtp-jf2Ivi4CrD88-AwmgRlQlBQRIRsuuD-n_AXn7ScVg</recordid><startdate>202408</startdate><enddate>202408</enddate><creator>Wang, Jianpeng</creator><creator>Xiao, Ping</creator><creator>Li, Xishan</creator><creator>Wu, Wenyu</creator><creator>Shi, Degang</creator><creator>Lin, Wei</creator><creator>Wu, Zuchang</creator><general>Elsevier Masson SAS</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202408</creationdate><title>Predictive value of circulating immune cell changes in response to PD-1 blockade and TKI therapy in patients with hepatocellular carcinoma</title><author>Wang, Jianpeng ; Xiao, Ping ; Li, Xishan ; Wu, Wenyu ; Shi, Degang ; Lin, Wei ; Wu, Zuchang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c241t-94f82703c0f8bba6b9737974784cd011cde41ae3579cc7f90e7482ea97072fc73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Aged</topic><topic>Carcinoma, Hepatocellular - blood</topic><topic>Carcinoma, Hepatocellular - drug therapy</topic><topic>Carcinoma, Hepatocellular - immunology</topic><topic>Chemoembolization, Therapeutic</topic><topic>Circulating immune cells</topic><topic>Female</topic><topic>Hepatocellular carcinoma</topic><topic>Humans</topic><topic>Immune Checkpoint Inhibitors - therapeutic use</topic><topic>Immunotherapy</topic><topic>Killer Cells, Natural - immunology</topic><topic>Liver Neoplasms - blood</topic><topic>Liver Neoplasms - drug therapy</topic><topic>Liver Neoplasms - immunology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Phenylurea Compounds - therapeutic use</topic><topic>Predictive Value of Tests</topic><topic>Programmed Cell Death 1 Receptor - antagonists & inhibitors</topic><topic>Protein Kinase Inhibitors - therapeutic use</topic><topic>Quinolines - therapeutic use</topic><topic>T-Lymphocytes - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Jianpeng</creatorcontrib><creatorcontrib>Xiao, Ping</creatorcontrib><creatorcontrib>Li, Xishan</creatorcontrib><creatorcontrib>Wu, Wenyu</creatorcontrib><creatorcontrib>Shi, Degang</creatorcontrib><creatorcontrib>Lin, Wei</creatorcontrib><creatorcontrib>Wu, Zuchang</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinics and research in hepatology and gastroenterology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Jianpeng</au><au>Xiao, Ping</au><au>Li, Xishan</au><au>Wu, Wenyu</au><au>Shi, Degang</au><au>Lin, Wei</au><au>Wu, Zuchang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Predictive value of circulating immune cell changes in response to PD-1 blockade and TKI therapy in patients with hepatocellular carcinoma</atitle><jtitle>Clinics and research in hepatology and gastroenterology</jtitle><addtitle>Clin Res Hepatol Gastroenterol</addtitle><date>2024-08</date><risdate>2024</risdate><volume>48</volume><issue>7</issue><spage>102390</spage><pages>102390-</pages><artnum>102390</artnum><issn>2210-7401</issn><issn>2210-741X</issn><eissn>2210-741X</eissn><abstract>•Circulating immune cells have shown to have a correlation with the response to immunotherapy in hepatocellular carcinoma patients.•Circulating immune cells have the potential to serve as indicators of the response to immunotherapy, providing a means to monitor dynamic changes and optimize treatment for HCC.•The number of circulating NK cells increased when patients with hepatocellular carcinoma received lenvatinib in combination with ICIs.•A low level of circulating CD3+t and CD4+t cells was associated with a poor prognosis.
Purpose: This study investigated the dynamic changes in circulating immune cells following immune checkpoint inhibitors (ICIs), tyrosine kinase inhibitors (TKIs), and interventional therapy in hepatocellular carcinoma (HCC).
Methods: HCC patients undergoing transarterial chemoembolization (TACE), TKI, and ICI treatment were included in the treatment group. Peripheral blood samples were collected from these patients before each cycle of PD-1 blockade treatment. Flow cytometry analysis was conducted to assess the composition of peripheral immune cells and identify PD-1-expressing T cells.
Results: The treatment group showed a median time-to-tumor progression (TTP) of 8 months and an overall survival (OS) of 19 months. In comparison, the control group had 6 months and 15 months respectively. These differences were statistically significant (P = 0.029 for TTP and P = 0.020 for OS). In HCC patients receiving Lenvatinib, more circulating natural killer (NK) cells were noted. After 1–2 cycles of PD-1 antibody treatment, a general decline in the proportion of circulating PD-1+T cells was found, indicating individual variations in response.
Conclusion: Circulating immune cells have the potential to serve as indicators of the response to immunotherapy, providing a means to monitor dynamic changes and optimize treatment for HCC.</abstract><cop>France</cop><pub>Elsevier Masson SAS</pub><pmid>38823631</pmid><doi>10.1016/j.clinre.2024.102390</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2210-7401 |
| ispartof | Clinics and research in hepatology and gastroenterology, 2024-08, Vol.48 (7), p.102390, Article 102390 |
| issn | 2210-7401 2210-741X 2210-741X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3063471791 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Aged Carcinoma, Hepatocellular - blood Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - immunology Chemoembolization, Therapeutic Circulating immune cells Female Hepatocellular carcinoma Humans Immune Checkpoint Inhibitors - therapeutic use Immunotherapy Killer Cells, Natural - immunology Liver Neoplasms - blood Liver Neoplasms - drug therapy Liver Neoplasms - immunology Male Middle Aged Phenylurea Compounds - therapeutic use Predictive Value of Tests Programmed Cell Death 1 Receptor - antagonists & inhibitors Protein Kinase Inhibitors - therapeutic use Quinolines - therapeutic use T-Lymphocytes - immunology |
| title | Predictive value of circulating immune cell changes in response to PD-1 blockade and TKI therapy in patients with hepatocellular carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T08%3A45%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Predictive%20value%20of%20circulating%20immune%20cell%20changes%20in%20response%20to%20PD-1%20blockade%20and%20TKI%20therapy%20in%20patients%20with%20hepatocellular%20carcinoma&rft.jtitle=Clinics%20and%20research%20in%20hepatology%20and%20gastroenterology&rft.au=Wang,%20Jianpeng&rft.date=2024-08&rft.volume=48&rft.issue=7&rft.spage=102390&rft.pages=102390-&rft.artnum=102390&rft.issn=2210-7401&rft.eissn=2210-741X&rft_id=info:doi/10.1016/j.clinre.2024.102390&rft_dat=%3Cproquest_cross%3E3063471791%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3063471791&rft_id=info:pmid/38823631&rft_els_id=S2210740124001116&rfr_iscdi=true |